Categories
Portfolio Company News

OMass Therapeutics Announces $310 Million Series C Financing to Advance Portfolio of Small Molecule Therapeutics in Endocrinology and Immunology

Categories
Portfolio Company News

Juvena Therapeutics Appoints Julie Anne Smith as Chief Executive Officer

Categories
Portfolio Company News

Draig Therapeutics Closes Oversubscribed $65 Million Series B to Accelerate Development of Highly Specific AMPA and GABAA Receptor Modulators in Neuropsychiatric Disorders

Categories
Portfolio Company News

FesariusTherapeutics Closes Oversubscribed $20M Series A, Led by Jefferson Life Sciences, and Backed by NY Ventures, and the American Society of Plastic Surgeons

Categories
Portfolio Company News

Juvena Therapeutics Raises $33.5M Series B Led by Bison Ventures to Advance Regenerative Biologics Pipeline